National Quality Measures Clearinghouse | Attention-deficit/hyperactivity disorder (ADHD) (continuation and maintenance phase): percentage of members 6 to 12 years of age with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the initiation phase ended.

National Quality Measures Clearinghouse | Attention-deficit/hyperactivity disorder (ADHD) (continuation and maintenance phase): percentage of members 6 to 12 years of age with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the initiation phase ended.:

"Title
Attention-deficit/hyperactivity disorder (ADHD) (continuation and maintenance phase): percentage of members 6 to 12 years of age with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the initiation phase ended.

Source(s)
National Committee for Quality Assurance (NCQA). HEDIS® 2011: Healthcare Effectiveness Data and Information Set. Vol. 1, narrative. Washington (DC): National Committee for Quality Assurance (NCQA); 2010. various p.

National Committee for Quality Assurance (NCQA). HEDIS® 2011: Healthcare Effectiveness Data and Information Set. Vol. 2, technical specifications. Washington (DC): National Committee for Quality Assurance (NCQA); 2010. various p.

National Quality Measures Clearinghouse | Attention-deficit/hyperactivity disorder (ADHD) (continuation and maintenance phase): percentage of members 6 to 12 years of age with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the initiation phase ended.: - Enviado mediante la barra Google"